Trials / Terminated
TerminatedNCT00054834
Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma
A Phase I Clinical Trial of Radiolabeled Immunotherapy With Humanized LL2 in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (planned)
- Sponsor
- Gilead Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the safety of 90Y-hLL2 at different dose levels in the treatment of Non-Hodgkin's lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | hLL2 (epratuzumab) |
Timeline
- Start date
- 2003-03-01
- First posted
- 2003-02-13
- Last updated
- 2021-08-16
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00054834. Inclusion in this directory is not an endorsement.